- Motley Fool•yesterday
GlaxoSmithKline and Novartis are two high-yield dividend stocks that might be grossly undervalued.
- Investopedia•3 days ago
Merck's HIV drug candidate doravirine (MK-1439) met its primary endpoint in a Phase 3 trial.
- Market Realist•3 days ago
As of February 13, 2017, GlaxoSmithKline is trading at a forward PE multiple of 14.2x. That's slightly lower than the industry average of 15.3x.
GSK.L : Summary for GLAXOSMITHKLINE PLC ORD 25P - Yahoo Finance
GlaxoSmithKline plc (GSK.L)
LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
|Bid||1,600.00 x 175400|
|Ask||1,640.00 x 417900|
|Day's Range||1,611.00 - 1,639.63|
|52 Week Range||1,355.00 - 1,745.56|
|PE Ratio (TTM)||87.65|
|Dividend & Yield||1.01 (4.89%)|
|1y Target Est||N/A|